The concept of point-of-care diagnostics – the rapid and sensitive detection of analytes at or near the patient – has been around for decades. Recent public health experiences, however, have propelled the urgency to develop and deploy point-of-care (PoC) tests into the limelight. Undoubtedly, molecular diagnostics plays an increasingly pivotal role in global health and, as the SARS-CoV-2 pandemic clearly revealed, is a first line of defense in understanding and managing future emergencies. The question is no longer ‘do we need to test onsite?’ but
‘how can we test around the world, regardless of location, climate, facilities, and testers?’